 NRAS mutations arise in 1520 of all melanomas and are associated with aggressive disease and poor prognosis . Besides the treatment for NRAS mutant melanoma are not very efficient and is currently limited to immune checkpoints inhibitors or aggressive chemotherapy . 4 nerolidylcathecol a natural product extracted from

@highlight 4 NC has antitumor effect in xenograft model of a NRAS mutant melanoma.
@highlight 4 NC shows a mild systemic toxicity when compared to other available therapies.
@highlight 4 NC decreases tumor size
@highlight by cytotoxicity and MMP inhibition.
@highlight 4 NC is a promising contributor to the therapeutic arsenal against melanoma.
